CD8A and liver disorder: Cyclopamine treatment (50 μM) of CD8 T cells alongside anti-CD3/CD28 stimulation ablated IFN-γ expression in bulk CD8 T cells regardless of liver disease severity (Figures 3A, B), in a dose-dependent manner (Supplementary Figure 3).